Unknown PHASE2 INTERVENTIONAL 2-arm NCT04692051

A Phase II Study for Nab-paclitaxel Plus Cisplatin vs Gemcitabine Plus Cispatin as First Line Chemotherapy in Advanced Biliary Tract Cancer

Sponsor: CSPC Ouyi Pharmaceutical Co., Ltd.

Interventions Gemcitabine + Cisplatin Nab-paclitaxel + Cisplatin

Updated 4 times since 2021 Last updated: Dec 29, 2020 Started: Sep 1, 2019 Primary completion: Mar 1, 2021 Completion: Sep 1, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Biliary Tract Cancer and is currently ongoing. CSPC Ouyi Pharmaceutical Co., Ltd. leads this study, which shows 4 recorded versions since 2019 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2023 — Jul 2024 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status
Jan 2021 — Jan 2023 [monthly]

Recruiting PHASE2

First recorded

Sep 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

CSPC Ouyi Pharmaceutical Co., Ltd.
Huazhong University of Science and Technology

Data source: Huazhong University of Science and Technology

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Wuhan, China